Has Christopher Ta, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,318 in general payments to Christopher Ta, MD across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Ta, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Ta, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Ta, MD

Ophthalmology · Stanford, CANPI 1609903020

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,430 of the $18,318 with a category attached, or 62.4%. 13 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 34.3% of the total. Reporting peaked in 2019 at $6,955 and has fallen 64.9% since, to $2,441 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,318in general payments, 2019–2025

Across 42 payments — averaging $436.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Kala Pharmaceuticals, Inc.$6K
Shire North American Group Inc$4K
Dompe Farmaceutici S.p.a.$2K
Seagen Inc.$2K
Alcon$1K
Amgen$1K
plus $1K from 7 others

$20,058in research payments, 2019–2025

Across 7 payments — averaging $2865.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$20K

What the payments were for

Consulting fees$11,43062%
Speaking & faculty fees$4,25023%
Food & beverage$2,63814%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Kala Pharmaceuticals, Inc.	8	$6,284
Shire North American Group Inc	4	$4,306
Dompe Farmaceutici S.p.a.	2	$2,410
Seagen Inc.	1	$1,680
Alcon	11	$1,190
Amgen	1	$1,125
Novartis	5	$499
Dompe US, Inc.	2	$236
Oyster Point Pharma, Inc.	3	$218
Ocular Therapeutix, Inc.	1	$162
Mallinckrodt Hospital Products Inc.	1	$100
Biotissue Holdings Inc.	2	$72
Sanofi	1	$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,318 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California →

Medicare billing

Part B allowed, 2024

$122,041

Medicare patients

372

Services billed

1,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RestasisCyclosporine	91	$114,934
XiidraLifitegrast	62	$66,790
Cyclosporine	51	$25,873
MieboPerfluorohexyloctane/Pf	22	$17,839
ValacyclovirValacyclovir Hcl	71	$5,011
Doxycycline Hyclate	106	$3,572
MoxifloxacinMoxifloxacin Hcl	78	$2,396
Prednisolone Acetate	52	$1,853
ErythromycinErythromycin Base	186	$1,647
Acyclovir	19	$402
Azithromycin	14	$143
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim	14	$97

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Stanford

Kuldev SinghStanford$1.5M
Daniel SchwartzSan Francisco$8M
Michael BerlinWest Hollywood$5.7M
Gilbert KlimanMenlo Park$1.5M
Raymond DouglasBeverly Hills$1.3M
John AffeldtLoma Linda$1.1M
Srinivas SaddaPasadena$1M
Sheri RowenNewport Beach$1M
Savak TeymoorianLaguna Hills$955K
Andrew MoshfeghiLos Angeles$895K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →